Last Week in Biomedicine | May 11–15 | Part 1
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
Last Week in Biomedicine | May 11–15 | Part 1
-
Letto da:
-
Di:
Top 10 significant clinical trial results from last week
Part 1:
1. REGENXBIO ($RGNX) — RGX-202 microdystrophin gene therapy for Duchenne muscular dystrophy (Phase 3)
2. Alkermes ($ALKS) — LUMRYZ (sodium oxybate once-nightly) for idiopathic hypersomnia (Phase 3)
3. Viking Therapeutics ($VKTX) — oral VK2735 (GLP-1/GIP dual agonist) for obesity (Phase 2)
4. Inhibrx Biosciences ($INBX) — INBRX-106 (hexavalent OX40 agonist) plus pembrolizumab for first-line PD-L1+ head and neck squamous cell carcinoma (Phase 2)
5. United Therapeutics ($UTHR) — Tyvaso (inhaled treprostinil) for idiopathic pulmonary fibrosis (Phase 3)
Subscribe for weekly clinical trial breakdowns at TrialBreaks.com
#biotech #clinicaltrials #pharma #genetherapy #Duchenne #DMD #GLP1 #obesity #oncology #immunotherapy #headandneckcancer #pulmonology #IPF #cysticfibrosis#womenshealth #prostatecancer #glioblastoma #ovariancancer #sleepmedicine